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Abstract
Background: Varicose veins affect up to 40% of men and up to 51% of women. The pathophysiology of primary varicosis is
poorly understood. Theories ranging from incompetence of the venous valves to structural changes in the vein wall have
been proposed.
Methodology/Principal Findings: We analyzed the functional state of the intramural smooth muscle cells (n = 14 pairs
matched for age and gender) and the expression of relaxin-2 and its receptors RXFP1 and RXFP2 in samples of varicose and
healthy great saphenous veins (GSV) (n = 21 healthy GSV; n = 46 varicose GSV). Relaxin-2 and RXFP1 contents were
determined in tissue samples (n = 9 samples per group). Pharmacological analyses were performed in a perfusion chamber.
Morphometric determination of the nuclear size of the smooth muscle compartment yielded no significant difference in
varicose GSV in comparison with the healthy controls. Relaxin-2 and its receptors were expressed in the muscular layer,
endothelial cells and in blood vessels contained in the vein wall. Immunohistochemical expression of relaxin-2, RXFP1 and
RXFP2 was significantly decreased in varicose GSV. Relaxin-2 and RXFP1 measured by ELISA and Western Blot were
decreased in varicose GSV (relaxin-2 ELISA healthy vs. varicose GSV: 12.4960.66 pg/mg versus 9.1263.39 pg/mg of total
protein; p = 0.01; Student’s T-test). Contractions of vein samples induced by cholinergic or adrenergic stimulation were
antagonized by relaxin-2.
Conclusions/Significance: We report that relaxin-2 and its receptors RXFP1 and RXFP2 are expressed in GSV and that their
expression is significantly decreased in varicose GSV. Further, we were able to demonstrate a functional pharmacological
relaxin-2 system in varicose GSV. Our results suggest a novel role for relaxin-2 in the pathogenesis of primary varicosis,
rendering relaxin-2 a novel possible pharmacological agent for the treatment of this widely prevailing venous disease.
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Introduction
Varicose veins affect up to 40% of men and up to 51% of
women. Western lifestyle, hormonal changes, age, female gender,
parity, adipositas and standing occupation are risk factors
associated with varicosis [1–3]. Little is known about the
pathophysiology of primary varicosis. Theories have been
proposed, such as functional abnormalities in the valve structures,
biological (matrix metalloproteinase (MMP) expression) or mor-
phologic changes of the vein wall (hypertrophy/loss of smooth
muscle cells) and extra-cellular matrix organization (collagen and
elastin content). However, conflicting data have been reported on
all these issues [4,5]. Recently, human thymic smooth muscle cells
were analyzed for MMP-2 expression and gelatinase activity under
experimentally-induced cyclic stretch as a surrogate for smooth
muscle cells from the tunica media of the GSV [6]. A gender-
specific expression of estrogen and progesterone in healthy and
varicose GSV was reported [7].
Relaxin belongs to the insulin-like growth factor family [8].
Three different relaxin genes have been found in humans, known
as RLN1, RLN2, and RLN3. Relaxin exerts its actions via its
leucine-rich-repeat-containing G-protein coupled receptors
(GPCR) RXFP1 and RXFP2. Upon receptor binding, intracellu-
lar relaxin signaling is mediated by Smad, MAPK, ERK, and PI3
kinase pathways. As ‘‘pregnancy hormone’’, relaxin promotes
elongation of the interpubic ligament in mammals, inhibits
spontaneous contractions of the uterine myometrium in guinea
pigs and promotes cervical softening in several species [9]. It is
produced in small quantities within the male reproduction tract
and has been detected in the human prostate. Further, relaxin is
involved in fibrosis, wound healing, cardiac protection, allergic
responses and cancer [9].
Of particular interest are the anti-fibrotic and the vasodilatory
effects of relaxin. Relaxin increases MMP-induced collagen
synthesis and decreases the actions of the tissue inhibitors of
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MMPs. Human relaxin-2 reverses pathological collagen accumu-
lation in numerous animal models of induced fibrosis [10].
Vasodilatory effects are mediated by promotion of nitric oxide
(NO) in addition to antagonism of the vasoconstricting actions of
endothelin-1 and angiotensin II [11].
In this study we analyzed the functional state of smooth muscle
cells of the tunica media in control and varicose GSV by nuclear
morphometry and studied a possible role for relaxin-2 in the
pathogenesis of varicosis by comparing the expression of relaxin-2,
RXFP1 and RXFP2 in control and varicose GSV. Moreover,
pharmacologic stimulation of samples of GSV was performed to
characterize the function of relaxin in GSV.
Results
Quantitative morphometric analysis of nuclear size of
smooth muscle cells
We investigated the functional state of smooth muscle cells in
the tunica media by measuring the nuclear size as quantitative
parameter. The projection area of the nucleus was taken as direct
parameter to estimate the volume of the nucleus, which correlates
with the functional state of the cell. Smooth muscle cells were
visualized in SMA staining for better contrasting and clear
identification (Fig. 1A). From the parallel HE stained slide, digital
images of 15 to 20 optical fields (magnification: 40x) were recorded
for measurement (Figs. 1B, C). An average of 1176 nuclei per GSV
were measured (Table 1 and Table S1). The standard deviation
(SD) in the measurement per patient is not only due to the
measuring error, but also due to the variation in the location of the
nuclei in the sections. This variation in the projection of the nuclei
was assumed to be identical in the specimens due to the high
number of measured nuclei. The average of the nuclear areas in
the group of control GSV was 29.269.3 mm2 compared to
30.1611.3 mm2 in the group of varicose veins (Figs. 1D, E). The
difference in nuclear size between healthy and varicose GSV was
not significant; however, the SD of the nuclear areas was higher in
the group of varicose GSV.
Immunohistochemical localization of relaxin-2, RXFP1
and RXFP2; measurement of relaxin-2 and RXFP1
proteins in samples of control and varicose GSV
The expression of relaxin-2, RXFP1 and RXFP2 was analyzed
in samples of 21 healthy (control) and 46 incompetent (varicose)
GSV (Table S2) by immunohistochemistry. In healthy GSV,
relaxin-2 and its receptors were strongly expressed in endothelial
cells, in smooth muscle cells of the tunica media, and in vasa
vasorum of the adventitia (Figs. 2A, B, C). In varicose GSV, the
principal expression pattern of relaxin-2, RXFP1 and RXFP2 was
similar to the healthy control veins (Figs. 2A, B, C). Evaluation of
proximal and distal samples of the same varicose GSV showed no
differences in expression of relaxin-2, RXFP1 and RXFP2 (not
shown). However, the expression levels (intensity) of relaxin-2,
RXFP1 and RXFP2 were significantly lower in varicose GSV
(Fig. 2D; p,0.01; Fishers’s Exact Test, two-tailed). For relaxin-2
and RXFP2 no influence of age or gender on protein staining
intensity was found. For RXFP1 we detected an age-independent
significant difference of staining intensity in the healthy control
GSV samples when comparing male and female donors. Females:
8/10 with strong expression of RXFP1; males: 2/11 with strong
expression of RXFP1 (p,0.01; Fisher’s Exact Test, two-tailed).
To verify the immunohistochemical data, relaxin-2 content was
determined using an ELISA assay in samples of 9 healthy and 9
varicose GSV (4 female and 5 male donors in each group). Here
too, the relaxin-2-level was significantly lower in varicose GSV
compared to the healthy controls (9.1263.39 pg/mg versus
12.4960.66 pg/mg of total protein; p = 0.01; Student’s T-test)
(Fig. 3A). Western Blot analyses in samples of 9 healthy (4 female,
5 male donors) and 11 varicose GSV (4 female, 7 male donors) also
demonstrated a reduced expression of RXFP1 in the varicose
GSV samples (Fig. 3B).
Ex-vivo pharmacology of KCl, arterenol, carbachol and
relaxin-2 in surgical samples of varicose GSV
To determine a functional relaxin-2-system in GSV, we
performed pharmacological testing with adrenergic and choliner-
gic stimuli to assess the contraction capacity of the smooth muscle
compartment and a possible modification thereof by relaxin-2. In
total, 7 different specimens of each GSV (from 2 female donors)
were used for the pharmacological stimulations with different
drugs. Figures 3C and D depict the results of an exemplary series
of stimulations. As expected, KCl induced a maximum contraction
of the vein wall (defined as 100% maximum contraction).
Adrenergic and cholinergic stimulations induced contractions that
were less pronounced than the KCl contraction (Arterenol: 76%;
Carbachol: 51% of KCl maximum concentration). Pulse stimu-
lation with relaxin-2 induced a relaxation of the tissue specimens
(corresponding to 234% of KCl maximum concentration;
Fig. 3C). A final stimulation with KCl was re-performed,
demonstrating a sustained vitality and contractability capacity of
the tissues (94% of original maximum concentration). The
pharmacological stimulations were repeated under constant
perfusion with relaxin-2. Relaxin-2 partly antagonized the
adrenergic and cholinergic contractions (Arterenol: 76 to 47%
(reduction of 29% of KCl maximum concentration); Carbachol:
51 to 23% (reduction of 28% of KCl maximum concentration;
Fig. 3D).
Discussion
Distensibility of the vein wall is controlled by smooth muscle
cells, collagen and elastin. The smooth muscle compartment of the
tunica media is responsible for wall tone, which is controlled by
autonomic nerves and circulating stimulants. Passive tone is
provided by collagen and elastin. Changes in collagen, elastin and
smooth muscle contents in varicose GSV leading to reduced
contractibility and compliance have been reported [4]. Relaxin
mediates smooth muscle relaxation and collagen turnover. Since
both aspects play important roles in the development of primary
varicosis, the aim of the present study was to determine the
expression pattern of relaxin-2 and its receptors RXFP1 and
RXFP2 in healthy and varicose GSV.
To assess the functional state of smooth muscle cells we used
nuclear size measurements as a quantitative parameter. Measure-
ment of nuclear size in histological sections is a reliable method for
the quantitative determination of the functional state of endocrine
organs and was used to elucidate the hypophyseal gonadal and
adrenal axis [12,13] and the smooth muscle cells in uterosacral
ligaments of patients with and without pelvic organ prolapse [14].
Since apoptosis is not detectable in the muscular compartment of
varicose GSV [15], nuclear size changes known to occur during
apoptosis had not to be taken into account. We observed no
differences of the cell nucleus area of smooth muscle cells in
healthy and varicose GSV. The mean nuclear size had a higher
standard deviation in the varicose group. Whether this possibly
reflects the disorganization of the muscular layer previously
described for varicose veins [2,3] remains to be elucidated.
It is not yet clear if primary varicosis is caused by endocrine
factors, inherent or acquired structural defects or external factors
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such as mechanical stress. Influences of the sex hormones estrogen
and progesterone on tissue metabolism in veins have been
suggested [7,15], however, a functional relevance for varicosis
could not be established. Our results revealed that the expression
of relaxin-2 and RXFP2 was reduced in the varicose GSV
independent of sex and age, suggesting a muted relaxin-system
leading to reduced short-term functionality of the smooth muscle
compartment and possibly responsible for long-term fibrotic
accumulation of collagen in the varicose vein wall. For RXFP1
expression we found an age-independent, significantly increased
expression in female healthy control GSV samples when
compared to healthy samples from male donors.
Functional pharmacology of life surgical samples under the
microscope confirmed the adrenergic and cholinergic nature of the
smooth muscle compartment of the GSV [1]. Moreover, it
demonstrated for the first time that relaxin-2 antagonized the
adrenergic and cholinergic contractions, suggesting that relaxin-2
might be also involved in short-term, active fine-tuning of the
active tone of the vein wall in addition to the long-term, passive
tone set up by collagen and elastin turnover. Relaxin-2 exerts its
short-term effects via NO induced in the smooth muscle cell or
secreted as relaxing factor from the endothelium [16]. The effect
of relaxin-2 on the sensitivity toward arterenol is well explained by
interference with smooth muscle contraction via NO production
and increased cGMP levels.
Limitations of the study were (i) the age difference of male and
female patient donors, which however had no effect on the
immunohistochemical expression of relaxin-2 and its receptors; (ii)
the imperfect matching of four out of the fourteen matched pairs
used for nuclear morphometry; (iii) the relatively low number of
healthy (control) GSV specimens (n = 9) analyzed in ELISA and
Western blot, and (iiii) the lack of pharmacological data on healthy
GSV samples. Therefore further studies are required to back up
the presented and in part preliminary data suggesting a
pathophysiological role for relaxin-2 in primary varicosis.
Together, we were able to demonstrate for the first time that
relaxin-2, RXFP1 and RXFP2 are less expressed in varicose GSV
compared to healthy GSV and that relaxin-2 antagonizes the
adrenergic and cholinergic contractions of the smooth muscle
compartment in GSV. Considering the smooth muscle-relaxing
and anti-fibrotic actions of relaxin, our findings strongly suggest
that the reduced expression of relaxin-2 in varicose GSV might
play a pivotal role in the pathogenesis of primary varicosis and
identify relaxin-2 as the first potential agent for pharmacological
treatment of primary varicosis.
Materials and Methods
Recruitment of patients and tissue specimens
Patients ,18 years, with post-menopausal hormonal replace-
ment therapy, pregnancy, severe chronic (autoimmune) diseases
(e.g. diabetes mellitus, cardiac insufficiency, lupus erythematodes),
stage IV tumor patients and patients with post-thrombotic reflux
in the GSV were excluded from this study. As healthy controls,
surplus GSV were obtained from two different sources: 1. Patients
undergoing elective coronary bypass surgery at the Department of
Thorax, Vascular, and Cardiac Surgery, University of Tuebingen,
Germany (n= 13). 2. Melanoma patients diagnosed with micro-
metastasis or single melanoma cells detected in the sentinel lymph
node biopsy undergoing radical inguinal lymph node dissection
(n= 8). GSVs of control patients were assessed by duplex
ultrasonography for reflux before operation by trained technicians.
None of the included control patients had duplex ultrasonograph-
ic, clinical or intraoperative signs of venous insufficiency or
varicosis (C0–C1).
Incompetent (varicose) GSV were obtained from patients with
primary varicosis (n = 26) during saphenectomy by stripping either
at the Department of Dermatology, University of Tuebingen, or at
the praxis clinic Dr. A. Bern/Prof. M. Moehrle at Tuebingen,
Germany. Preoperative evaluation of vein status was obtained by
duplex ultrasonography by trained technicians, showing retro-
grade flow all along the venous GSV-axis (sapheno-femoral
junction, long saphenous vein and perforating veins) (C2–C4).
None of the varicosis patients presented with venous ulcers (C5–
C6). In summary, the varicose patients were C2–4EpAs/pPr. The
healthy control patients were C0–1EnAnPn. For histological and
immunohistochemical analysis, 20 additional samples of paraffin
embedded varicose GSV derived from GSV stripping operations
from patients with primary varicosis (C2–4EpAs/pPr)were retrieved
from the files of the Department of Pathology, University of
Tuebingen to increase the number of samples. Details (age and
gender) of the patients included in this study: Control patients:
female: n = 10, mean age: 74 years; male: n = 11, mean age:
66 years; combined mean age: 70 years. Varicose patients: female:
n = 30, mean age: 57 years; male: n = 11, mean age: 50 years;
combined mean age: 53 years (see also Table S2).
Figure 1. Morphometry of smooth muscle cell nuclei of the tunica media of GSV. (A) Representative cross-section of a GSV. Smooth muscle
cell compartment is visualized by smooth muscle actin staining. (B, C) Morphometry was conducted on HE stained slides (using Zeiss Axiovision).
Statistical analysis of nuclear measurements of paired healthy (D) and varicose (E) GSV specimens demonstrating no significant difference of nuclear
size in varicose GSV compared to healthy GSV.
doi:10.1371/journal.pone.0039021.g001
Table 1. Cell nucleus areas of 14 pairs of healthy and varicose
GSV samples.
Pair no. GSV Varicose GSV
Cell nucleus area
[mm2] n
Cell nucleus area
[mm2] N
1 31,0469,90 1157 38,73612,10 978
2 27,8568,64 967 35,2369,64 875
3 35,7069,57 697 37,54615,03 588
4 28,7368,30 1239 35,9769,32 966
5 30,2569,12 759 46,65611,72 1310
6 29,6768,55 1364 25,8767,19 1170
7 38,45610,69 962 31,3269,02 1070
8 30,0468,25 913 21,8666,47 1191
9 33,5768,13 1337 30,0668,27 1508
10 26,4968,27 1372 30,1268,87 1350
11 26,6968,38 1489 21,0965,93 1559
12 24,2766,81 1822 26,4166,04 1249
13 28,4668,41 1148 21,2365,28 1363
14 25,4367,11 1309 30,0567,24 1210
Mean 29,17 30,12
SD 9,25 11,33
doi:10.1371/journal.pone.0039021.t001
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Figure 2. Immunohistochemical detection of relaxin-2 and its receptors RXFP1 and RXFP2 in healthy and varicose GSV. (A) Anti-
relaxin-2-staining strongly labels endothelial cells, the tunica media and vasa vasorum of the adventitia in healthy GSV and less intense in
corresponding compartments of varicose GSV. (B, C) Both RXFP1 and RXFP2 show decreased staining intensity in similar compartments in varicose
GSV compared to healthy GSV. (D) Statistical evaluation of staining score.
doi:10.1371/journal.pone.0039021.g002
Figure 3. Expression of relaxin-2 and its receptor RXFP1 in surgical samples of healthy and varicose GSV, and pharmacological
stimulation. (A) Relaxin-2 content is decreased in varicose compared to healthy GSV, determined by ELISA (9.1263.39 pg/mg versus
12.4960.66 pg/mg of total protein; p = 0.01; Student’s T-test). (B) Western Blot detection of RXFP1 in healthy and varicose GSV. RXFP1 bands are less
pronounced in the varicose GSV samples. (C) In vitro pharmacology of surgical samples of GSV. Pulse-stimulations with KCl (kaliumchloride), arterenol
(norepinephrinehydrochloride) and carbachol (carbamylcholine) induce contractions of the GSV specimens; relaxin-2 relaxes the specimens. The first
KCl contraction was defined as 100% maximum contraction. Arterenol: 76%, carbachol: 51%, relaxin-2: 234% of maximum KCl contraction. (D)
Constant perfusion with relaxin-2 partly antagonizes the contractions induced by pulse-stimulations with arterenol and carbachol: Arterenol: 76 to
47% (reduction of 29% of KCl maximum concentration), carbachol: 51 to 23% (reduction of 28% of KCl maximum concentration.
doi:10.1371/journal.pone.0039021.g003
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Removal of saphenous veins and processing
About 5–10 cm samples of GSV of both groups were obtained
during surgery. In some cases entire varicose GSV were obtained
after stripping operation. From these veins proximal and distal
samples were used. Tissue specimens were cut into three sections:
One third was transferred into 4uC PBS and directly transported
to the laboratory. For protein extraction, the second third was
snap-frozen and stored in liquid nitrogen until protein extraction.
For immunohistochemical analysis the last third of the tissue was
immediately fixed in 4uC buffered paraformaldehyde for 24 h.
After rinsing, the samples were embedded in paraplast using a
tissue processor (Shandon Citadel, Thermo Fisher Scientific,
Dreieich, Germany). Serial sections of 3 mm were cut (longitudinal
and transversal to the course of the veins), mounted onto polylysin-
coated slides and stained with Hematoxylin and Eosin (H&E) for
histological evaluation. For histological and immunohistochemical
analysis, additional samples of paraffin embedded varicose GSV
were retrieved from the files of the Department of Pathology,
University of Tuebingen, Germany. For protein extraction, a pre-
cooled mortar and pestle was used. The tissue samples were
minced in liquid nitrogen, the frozen powder was dissolved in
RIPA buffer (Sigma, Munich, Germany) 20 min on ice for cell
lysis and protein extraction, followed by 15 min centrifugation at
4uC. The supernatant was frozen until further evaluation. Protein
content was determined by Bradford assay.
Histological staining and immunohistochemistry
The primary antibodies used in this study were anti-human
relaxin-2 (1:300, rabbit, polyclonal, Immundiagnostik AG, Ben-
sheim, Germany), anti-relaxin receptor 1 (anti-RXFP1, 1:50,
rabbit, polyclonal, GenWay, San Diego, CA, USA), anti-relaxin
receptor 2 (anti-RXFP2, 1:50, rabbit, polyclonal, Genway), and
smooth muscle a-actin (SMA, 1:100, IgG2a, kappa, clone 1A4,
DAKO, Hamburg, Germany).
Immunostaining was carried out using standard protocols.
Briefly, sections were de-waxed in xylene, and rehydrated in
grades of industrial methylated spirit and distilled water.
Endogenous peroxidase activity was then quenched using
hydrogen peroxide for 10 min. After two washes in de-ionized
H2O and phosphate-buffered saline (PBS), sections were blocked
for 15 min with PBS containing 3% bovine serum albumin
(BSA), and then further blocked for 30 min with normal serum
to minimize non-specific reactivity. Further blocking was
performed with avidin-biotin blocking solution. The slides were
incubated overnight at 4uC with the primary antibody in a
humidified chamber. Sections were incubated with the secondary
antibody, then with peroxidase for 30 min each. Bound
antibodies were visualized with 0.5% diaminobenzidine (DAB)
in 0.5 mol/l tris-HCl pH 7.4, and 0.01% hydrogen peroxide
according to the manufacturer’s instructions (Dako, Germany).
After washing with distilled water the slides were counterstained
for 2–3 min with Mayer’s Hemalum. Sections were dehydrated
through graded ethanol, cleared with xylene and permanently
mounted in DEPEX. Negative control sections were produced by
omission of the primary antibody and did not show any staining,
while the positive control slides (human endometrium and
myometrium) were stained with the primary antibody, and there
was no background reaction. The positive staining controls are
depicted as Figure S1A. For immunohistochemical analyses,
paraffin sections of samples of 21 control GSV and 46 varicose
GSV were used (Table S2).
Image analysis, nuclear size morphometry and evaluation
of immunohistochemistry
Digital images were acquired using an Axioplan 2 microscope
(Carl Zeiss, Jena, Germany) with a mounted digital camera (Zeiss
AxioCam color, Carl Zeiss) and analyzed with image analysis
software (Zeiss Axiovision 4.2, Carl Zeiss; Adobe Photoshop CS2,
Adobe Systems GmbH, Munich, Germany). To assess the
functional state of the smooth muscle cells the nuclear area was
measured in H&E sections. The smooth muscle cell nucleus has a
rod shaped form with blunted edges. The computer-assisted
morphometry allows direct determination of the projection area of
the nuclei. Thus, the calculation of area or volume on the basis of
assumed geometric forms, and determination of diameters were
not necessary. Due to the orientation of the specimen in the
paraffin blocks the circular part of the tunica media was in general
cut in longitudinal direction. Cross-sectional areas were excluded
from the nuclear measurement. Cell nucleus size was measured on
the H&E slides because of better contrasting of the nuclei.
Morphometry of longitudinally cut smooth muscle cell nuclei of
the tunica media in cross sections of the veins was performed as
described previously in detail for smooth muscle cells in samples of
human sacrouterine ligaments [14]. For morphometric measure-
ments, control and varicose GSV were matched to 14 pairs
(Table S1) according to age and gender. In 10/14 pairs the
matching was successful; the remaining four pairs were matched
according to age (one pair), according to gender (one pair) or
according to the diagnosis alone (two pairs). The measuring person
(JA) was blinded to the clinical diagnosis, and slides were measured
in a random order. Slides stained for relaxin-2, RXFP1 and
RXFP2 were analyzed blinded to the clinical diagnosis in every
case. A semi-quantitative staining score was established (0/+/++/
+++; see Figure S1B), and all slides were classified accordingly.
ELISA
For detection and quantification of relaxin-2, a commercially
available Relaxin-2 ELISA KIT (Immundiagnostik AG) was used
according to the manufacturer’s instructions. Briefly, the assay
utilized the ‘‘sandwich’’ technique with two selected polyclonal
antibodies that bind to human relaxin-2. Assay standards and pre-
diluted GSV samples were added into the wells of a microplate
coated with a high affine polyclonal anti-human relaxin-2
antibody. During the first incubation step (4uC, 16 h), relaxin-2
was bound by the immobilized antibody. Then a detection
antibody, biotin-labeled anti relaxin-2, was added for 2 h at 4uC.
Afterwards a peroxidase conjugate was added to form a
‘‘sandwich’’ of capture antibody – human relaxin-2-detection
antibody–peroxidase-conjugate. Tetramethylbenzidine (TMB) was
used as peroxidase substrate (incubation: 1 h at 4uC). Acidic stop
solution was added to terminate the reaction. The color changed
from blue to yellow. The intensity of the yellow color is directly
proportional to the concentration of relaxin-2. A dose response
curve of the absorbance unit (optical density, OD at 450 nm) vs.
concentration was generated using the values obtained from the
standard. Relaxin-2 present in the GSV samples was determined
directly from this curve.
Western blot
15 mg protein of each GSV sample (see above) were subjected to
SDS–PAGE and transferred to polyvinylidene difluoride mem-
branes. After blocking in PBS/0.1% Tween-20/5% dry milk for at
least 1 h, the blots were probed overnight with primary antibodies
in PBS/0.1% Tween-20/5% dry milk, washed with PBS for
3610 min and incubated with secondary biotin-conjugated
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antibody (Dako, Grostrup, Denmark). After washing with PBS for
3610 min, the Streptavidin–Alkaline–Phosphatase conjugate
(Roche) was used for the detection of biotin-labeled secondary
antibody. The membrane was immersed in CDP-Star solution
(Roche) for 10 min and then exposed to X-ray film (Eastman
Kodak, Rochester, NY). The following primary antibodies were
used: anti-RXFP1 (1:1000, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and anti-b-actin (1:1000, Cell Signaling,
Frankfurt, Germany).
Pharmacology: Equipment, application of drugs, data
acquisition and evaluation
Pharmacological stimulation was performed on two samples of
varicose GSV (female donors, age 41 and age 54) to determine
whether adrenergic, cholinergic and relaxin-2 stimulation were
able to induce contraction or relaxation of the muscular
compartment. The central instrument was a stereomicroscope
(Stemi IV, Zeiss) equipped with a digital camera (Olympus). The
open perfusion chamber consisted of a rubber gasket (inner
diameter 0.8 cm) glued to a microscope slide and perforated with
three syringes, two for inlet (for perfusion medium without and
with relaxin-2, respectively) and one for outlet. The temperature of
37uC was controlled via a heated object stage and a heating plate
(Zeiss), onto which coils of the afferent perfusion tubes and the
tube for gas supply (carbogen, 95% O2 and 5% CO2) were fixed
under styrofoam insulation. The heated and moistened gas stream
was directed on the surface of the perfusion medium in the
chamber. Continuous perfusion with carbonate buffered Hanks
solution +2.5% 1 M Hepes was maintained by a peristaltic pump
(Type ISM597A, Ismatec SA, Zuerich, Switzerland) and afferent
and efferent silicon tubes. Small straps of longitudinally and
circularly cut GSV and cross sections were used after careful
removal of endothelium and the tunica adventitia with forceps and
bent scissors. The tissues were carefully placed into the perfusion
chamber.
The following drugs were used for bolus stimulation: KCl
(kaliumchloride, 1 mM, Fresenius Kabi, Bad Homburg, Ger-
many), arterenol (norepinephrine hydrochloride, noradrenaline,
1023 M, Sanofi-Aventis, Frankfurt, Germany), carbachol (carba-
mylcholine, 6.6 M, Sigma), recombinant human relaxin-2 (10 mg/
ml, Immundiagnostik AG). After each series of stimulation (KCl,
norepinephrine hydrochloride, carbachol, relaxin-2) a final
stimulation with KCl was re-performed to assure viability/
contractability of the tissues. As negative control perfusion with
HBSS was performed.
Drugs were applied by aspiration via the influx tube. During
relocation of the afferent silicone tube the peristaltic pump was
switched off for about 5 sec to avoid bubble formation. Pulse
stimulation was performed by aspiration of 200 ml of the respective
drug solution via the afferent silicon tube. The drug reached the
chamber within 75 sec through the afferent silicone tubes (one for
solutions without and one for solutions with relaxin-2) with an
inner diameter of 0.44 mm, a length of 1.3 m including the coils
on the heated microscope stage, a volume of 198 ml, and a flow
rate of 140 ml per minute. The volume of the chamber was 500 ml.
The effective maximum drug concentration during the pulse
stimulation was estimated by assuming a dilution factor of 0.5 for
the inflowing drug and an elimination factor of another 0.5 due to
efflux with the same rate. Thus in the pulse stimulation
experiments the effective drug concentration was one order of
magnitude lower than in the 200 ml applied. Between consecutive
pulse stimulation sequences the transfer of the 700 images of a
sequence to the database took about 3 min during which the
probe was rinsed with medium. In addition to the pulse
stimulations, the experiments were repeated under constant
perfusion with relaxin-2 (100 ng/ml in HBSS +11 mM glucose)
instead of the medium described above.
For each pharmacological stimulation a sequence of 700 images
with a resolution of 137661032 pixel and a file size of 1.85 GB
was recorded. The time-lapse factor was 0.5 seconds (length of
sequence: 5 minutes 50 seconds). For analysis of the tissue
contractions/dilations, the dimensions of the tissues (of images 1
and 700 of each stimulation) were measured (length/width of the
tissue straps, or diameter of cross-sections, respectively) by using
image analysis software (Zeiss Axiovision 4.2, Carl Zeiss). The
change of dimension after the first KCl stimulation was defined as
100% contraction, and the subsequent changes of dimension after
the other stimulations of the same tissue sample were calculated as
percentage of the 100% primary KCl contraction.
Statistical analysis
For the statistical analysis of immunohistochemical evaluation,
two groups of samples were clustered: – and + (low expression),
versus ++ and +++ (strong expression). Statistical analysis of
morphometric data and immunohistochemical evaluation were
performed by using Student’s T-test, Fisher’s Exact Test and
Wilcoxon Test. P-values ,0.05 were considered as statistically
significant. Statistical analysis was performed by SPSS Version
11.5 (SPSS GmbH Software, Munich).
Supporting Information
Figure S1 Human uterus control stainings for relaxin-2,
RXFP1 and RXFP2, and staining score. (A) Human
endometrium and myometrium was used as positive control for
immunohistochemistry. As expected, expression of relaxin-2 and
its receptors is restricted to endometrium and myometrium. (B) A
four-step staining score was applied to evaluate immunohisto-
chemical expression of relaxin-2, RXFP1 and RXFP2; shown are
images of anti-relaxin-2 staining. Scale bars = 50 mm.
(TIF)
Table S1 Age and gender of the 14 pairs of healthy and
varicose GSV used for nuclear morphometry.
(DOC)
Table S2 Age and gender of the donor’s of healthy and
varicose GSV samples used for immunohistochemical
analysis of relaxin-2, RXFP1 and RXFP2-expression.
(DOC)
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